Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Cytalux (Pafolacianine) for Intraoperative Detection of Tumor Tissue in Patients Undergoing Surgical Resection for Digestive System, Genitourinary System and Female Reproductive System Cancers

Trial Status: active

This phase II trial tests how well Cytalux, registered trademark, (pafolacianine) detects tumor cells using near-infrared (NIR) fluorescent imaging during surgery (intraoperative) in patients undergoing surgery for digestive system, genitourinary system or female reproductive system cancer. Pafolacianine is a fluorescent imaging agent that targets folate receptors (FR) which are overexpressed in many tumors and is used with NIR imaging during surgery to identify tumor cells. NIR imaging uses a special camera that uses wavelengths in the infrared range to visualize and locate the tumor cells that are lit up by the pafolacianine. Intraoperative pafolacianine with NIR imaging may improve tumor cell detection for removal in patients undergoing surgery for digestive system, genitourinary system or female reproductive system cancer.